Seattle Genetics Inc (SGEN) 54.08 $SGEN Seattle
Post# of 273254
Posted On: 09/20/2016 9:11:59 AM
Seattle Genetics Inc (SGEN) 54.08 $SGEN
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
BusinessWire - Mon Sep 19, 7:00AM CDT
--- Preclinical Data Showing Potent Anti-Leukemic Activity of SGN-CD123A Presented at the 2015 American Society of Hematology Annual Meeting-
SGEN: 54.08 (+0.43)
Upgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Fri Sep 16, 3:14AM CDT
Seattle Genetics (NASDAQ:SGEN) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $53.59 on volume of 1.2 million shares, above average daily volume of 954,000. In the past 52 weeks, shares of Seattle Genetics have traded between a low of $26.02 and a high of $54.74 and closed yesterday at $53.59, which is 106% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.8% while the 50-day MA has advanced 1.0%.
SGEN: 54.08 (+0.43)
Downgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Fri Sep 16, 3:13AM CDT
Seattle Genetics (NASDAQ:SGEN) was downgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $53.59 on volume of 1.2 million shares, above average daily volume of 954,000. In the past 52 weeks, Seattle Genetics share prices have been bracketed by a low of $26.02 and a high of $54.74 and closed yesterday at $53.59, 106% above that low price. The 200-day and 50-day moving averages have moved 0.82% lower and 1.00% higher over the past week, respectively.
SGEN: 54.08 (+0.43)
Watch for Seattle Genetics to Potentially Pullback After Gaining 2.09% Yesterday
Comtex SmarTrend(R) - Mon Sep 12, 1:52PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $49.50 to a high of $51.48. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $51.31 on volume of 382,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 54.08 (+0.43)
Seattle Genetics Set to Possibly Pullback After Yesterday's Rally of 4.74%
Comtex SmarTrend(R) - Wed Sep 07, 5:02PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $46.92 to a high of $48.84. Yesterday, the shares gained 4.7%, which took the trading range above the 3-day high of $46.33 on volume of 513,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 54.08 (+0.43)
Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Sep 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
SGEN: 54.08 (+0.43), MS: 31.60 (+0.01)
Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma
PR Newswire - Tue Aug 30, 7:15AM CDT
The Biotech arena includes companies that use biological processes to develop technological solutions, and manufacture products intended to improve the quality of life. Stocks under assessment on Stock-Callers.com today are: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Inovio Pharmaceuticals Inc. (NASDAQ: INO), Seattle Genetics Inc. (NASDAQ: SGEN), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up today and download for free the research reports for the stocks covered today at:
INO: 9.21 (-0.03), ARWR: 7.30 (+0.22), SGEN: 54.08 (+0.43), KERX: 4.74 (+0.04)
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS(R) (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
BusinessWire - Mon Aug 01, 5:59AM CDT
---Abstract to be Submitted to ASH for Presentation at the 2016 Annual Meeting-
SGEN: 54.08 (+0.43)
Learn how to target a 13% return on Under Armour, or get option-trade ideas on SPDR Gold Trust, Seattle Genetics, Priceline and Lockheed Martin Corporation or any stock you choose
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GLD, LMT, PCLN, SGEN, and UA.
UA: 38.74 (-0.17), LMT: 241.37 (+0.49), SGEN: 54.08 (+0.43), GLD: 125.34 (+0.02), PCLN: 1,448.06 (-11.99)
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
PR Newswire - Sat Jun 11, 1:30AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
SGEN: 54.08 (+0.43)
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
SGEN: 54.08 (+0.43)
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 54.08 (+0.43)
Seattle Genetics Rises 5.91% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:37PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $40.40 to a high of $43.37. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $41.14 on volume of 663,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 54.08 (+0.43)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 41.68 (-0.19), JNJ: 117.66 (-0.59), SGEN: 54.08 (+0.43), SNY: 39.37 (+0.67)
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
BusinessWire - Wed May 25, 7:00AM CDT
---Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial-
SGEN: 54.08 (+0.43)
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
BusinessWire - Mon Sep 19, 7:00AM CDT
--- Preclinical Data Showing Potent Anti-Leukemic Activity of SGN-CD123A Presented at the 2015 American Society of Hematology Annual Meeting-
SGEN: 54.08 (+0.43)
Upgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Fri Sep 16, 3:14AM CDT
Seattle Genetics (NASDAQ:SGEN) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $53.59 on volume of 1.2 million shares, above average daily volume of 954,000. In the past 52 weeks, shares of Seattle Genetics have traded between a low of $26.02 and a high of $54.74 and closed yesterday at $53.59, which is 106% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.8% while the 50-day MA has advanced 1.0%.
SGEN: 54.08 (+0.43)
Downgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Fri Sep 16, 3:13AM CDT
Seattle Genetics (NASDAQ:SGEN) was downgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $53.59 on volume of 1.2 million shares, above average daily volume of 954,000. In the past 52 weeks, Seattle Genetics share prices have been bracketed by a low of $26.02 and a high of $54.74 and closed yesterday at $53.59, 106% above that low price. The 200-day and 50-day moving averages have moved 0.82% lower and 1.00% higher over the past week, respectively.
SGEN: 54.08 (+0.43)
Watch for Seattle Genetics to Potentially Pullback After Gaining 2.09% Yesterday
Comtex SmarTrend(R) - Mon Sep 12, 1:52PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $49.50 to a high of $51.48. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $51.31 on volume of 382,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 54.08 (+0.43)
Seattle Genetics Set to Possibly Pullback After Yesterday's Rally of 4.74%
Comtex SmarTrend(R) - Wed Sep 07, 5:02PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $46.92 to a high of $48.84. Yesterday, the shares gained 4.7%, which took the trading range above the 3-day high of $46.33 on volume of 513,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 54.08 (+0.43)
Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Sep 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
SGEN: 54.08 (+0.43), MS: 31.60 (+0.01)
Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma
PR Newswire - Tue Aug 30, 7:15AM CDT
The Biotech arena includes companies that use biological processes to develop technological solutions, and manufacture products intended to improve the quality of life. Stocks under assessment on Stock-Callers.com today are: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Inovio Pharmaceuticals Inc. (NASDAQ: INO), Seattle Genetics Inc. (NASDAQ: SGEN), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up today and download for free the research reports for the stocks covered today at:
INO: 9.21 (-0.03), ARWR: 7.30 (+0.22), SGEN: 54.08 (+0.43), KERX: 4.74 (+0.04)
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS(R) (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
BusinessWire - Mon Aug 01, 5:59AM CDT
---Abstract to be Submitted to ASH for Presentation at the 2016 Annual Meeting-
SGEN: 54.08 (+0.43)
Learn how to target a 13% return on Under Armour, or get option-trade ideas on SPDR Gold Trust, Seattle Genetics, Priceline and Lockheed Martin Corporation or any stock you choose
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GLD, LMT, PCLN, SGEN, and UA.
UA: 38.74 (-0.17), LMT: 241.37 (+0.49), SGEN: 54.08 (+0.43), GLD: 125.34 (+0.02), PCLN: 1,448.06 (-11.99)
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
PR Newswire - Sat Jun 11, 1:30AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
SGEN: 54.08 (+0.43)
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
SGEN: 54.08 (+0.43)
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 54.08 (+0.43)
Seattle Genetics Rises 5.91% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:37PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $40.40 to a high of $43.37. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $41.14 on volume of 663,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 54.08 (+0.43)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 41.68 (-0.19), JNJ: 117.66 (-0.59), SGEN: 54.08 (+0.43), SNY: 39.37 (+0.67)
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
BusinessWire - Wed May 25, 7:00AM CDT
---Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial-
SGEN: 54.08 (+0.43)
(0)
(0)Scroll down for more posts ▼